IgG4-related disease: Results from a multicenter Spanish registry

Medicine (United States)

Volumn 94, Issue 32, 2015, Pages

  Fernández Codina, Andreu ^a   Martínez Valle, Fernando ^a   Pinilla, Blanca ^b   López, Cristina ^b   De Torres, Inés ^a   Solans Laqué, Roser ^a   Fraile Rodríguez, Guadalupe ^c   Casanovas Martínez, Arnau ^d   López Dupla, Miguel ^a   Robles Marhuenda, Ángel ^f   Barragán González, María Jesus ^g   Cid, Maria Cinta ^h   Prieto González, Sergio ^h   Brito Zerón, Pilar ^h   Cruces Moreno, María Teresa ⁱ   Fonseca Aizpuru, Eva ^j   López Torres, Manuel ^e,k   Gil, Judith ^l   Nuñez Fernández, Manuel Jesús ^m   Pardos Gea, José ^a   Salvador Cervelló, Gonzalo ⁿ   Astete, Carlos Guillen ^o   more..

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d Consorci Sanitari Parc Taulí ^*  (Spain)

^e HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g HOSPITAL VALLE DEL NALÓN   (Spain)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^j HOSPITAL DE CABUEÑES   (Spain)

^k HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^l HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^m HOSPITAL MONTECELO   (Spain)

ⁿ Hospital Manises   (Spain)

^o NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BIOLOGICAL PRODUCT; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PREDNISONE;

ADULT; ANCA ASSOCIATED VASCULITIS; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL FEATURE; CONSENSUS; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN G4 RELATED DISEASE; LACRIMAL GLAND; MAJOR CLINICAL STUDY; MALE; MAXILLARY SINUS; MIDDLE AGED; MULTICENTER STUDY; ORBIT PSEUDOTUMOR; PANCREAS; PRIORITY JOURNAL; RETROPERITONEUM; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SALIVARY GLAND; SPAIN; SPANIARD; TREATMENT RESPONSE; AUTOIMMUNE DISEASES; CLINICAL TRIAL; PARAPROTEINEMIAS; PATHOLOGY; REGISTER;

AUTOIMMUNE DISEASES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; PARAPROTEINEMIAS; REGISTRIES; SPAIN;

EID: 84942436818     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001275     Document Type: Article

References (23)

1. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012; 366: 539-551.
2. Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001; 344: 732-738.
3. Kamisawa T, Okamoto A. IgG4-related sclerosing disease. World J Gastroenterol. 2008; 14: 3948-3955.
4. Masaki Y, Dong L, Kurose N, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis. 2009; 68: 1310-1315.
5. Brito-Zerón P, Ramos-Casals M, Bosch X, et al. The clinical spectrum of IgG4-related disease. Autoimmun Rev. 2014; 13: 1203-1210.
6. Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012; 25: 1181-1192.
7. Stone JH, Khosroshahi A, Deshpande V, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum. 2012; 64: 3061-3067.
8. Yamamoto M, Yajima H, Takahashi H, et al. Everyday clinical practice in IgG4-related dacryoadenitis and/or sialadenitis: results from the SMART database. Mod Rheumatol. 2014; 27: 1-6.
9. Ebbo M, Daniel L, Pavic M, et al. IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. Medicine (Baltimore). 2012; 91: 49-56.
10. Fernández-Codina A, Martínez-Valle F, Castro-Marrero J, et al. Idiopathic retroperitoneal fibrosis: IgG4 infiltration in a cohort of Spanish patients. Rheumatol Int. 2014; 34: 1263-1265.
11. Chari ST, Kloeppel G, Zhang L, et al. Histopathologic and clinical subtypes of autoimmune pancreatitis: the Honolulu consensus document. Pancreatology. 2010; 10: 664-672.
12. Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012; 22: 21-30.
13. Umehara H, Nakajima A, Nakamura T, et al. IgG4-related disease and its pathogenesis-cross-talk between innate and acquired immunity. Int Immunol. 2014; 26: 585-595.
14. Carruthers MN, Khosroshahi A, Augustin T, et al. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis. 2015; 74: 14-18.
15. Wallace ZS, Mattoo H, Carruthers M, et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis. 2015; 74: 190-195.
16. Kamisawa T, Okazaki K, Kawa S, et al. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol. 2014; 49: 961-970.
17. Bosco JJ, Suan D, Varikatt W, et al. Extra-pancreatic manifestations of IgG4-related systemic disease: a single-centre experience of treatment with combined immunosuppression. Intern Med J. 2013; 43: 417-423.
18. Scheel PJ Jr, Feeley N, Sozio SM. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series. Ann Intern Med. 2011; 154: 31-36.
19. Alberici F, Palmisano A, Urban ML, et al. Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. Ann Rheum Dis. 2013; 72: 1584-1586.
20. Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut. 2013; 62: 1607-1615.
21. Khosroshahi A, Carruthers MN, Deshpande V, et al. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore). 2012; 91: 57-66.
22. Carruthers MN, Stone JH, Deshpande V, et al. Development of an IgG4-RD Responder Index. Int J Rheumatol. 2012; 2012: 259-408.
23. Hirano K, Tada M, Sasahira N, et al. Incidence of malignancies in patients with IgG4-related disease. Intern Med. 2014; 53: 171-176.